Hepatitis B reactivation after chemotherapy: two decades of clinical research

[1]  H. Kohrt,et al.  Antiviral prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. , 2007, Clinics in liver disease.

[2]  T. Mok,et al.  Hepatitis B viral load predicts survival of HCC patients undergoing systemic chemotherapy , 2007, Hepatology.

[3]  N. Schnepf,et al.  Reactivation of lamivudine-resistant occult hepatitis B in an HIV-infected patient undergoing cytotoxic chemotherapy. , 2007, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[4]  I. Bakulin,et al.  Treatment of Chronic Hepatitis B with Lamivudine in Renal Transplant Recipients , 2007, The International journal of artificial organs.

[5]  D. Shouval,et al.  Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies , 2007, British journal of haematology.

[6]  G. Colucci,et al.  COBAS AmpliPrep-COBAS TaqMan Hepatitis B Virus (HBV) Test: a Novel Automated Real-Time PCR Assay for Quantification of HBV DNA in Plasma , 2007, Journal of Clinical Microbiology.

[7]  William M. Lee,et al.  Aminotransferase elevation in HIV/hepatitis B virus co-infected patients treated with two active hepatitis B virus drugs. , 2006, AIDS patient care and STDs.

[8]  C. Derancourt,et al.  Late lethal hepatitis B virus reactivation after rituximab treatment of low‐grade cutaneous B‐cell lymphoma , 2006, The British journal of dermatology.

[9]  J. Luk,et al.  Comparison of Real-Time PCR Assays for Monitoring Serum Hepatitis B Virus DNA Levels during Antiviral Therapy , 2006, Journal of Clinical Microbiology.

[10]  J. Luk,et al.  Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. , 2006, Gastroenterology.

[11]  Chee-Kin Hui,et al.  Current issues and future directions in treatment. , 2006, Seminars in liver disease.

[12]  W. Yeo,et al.  Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy , 2006, Hepatology.

[13]  J. Jang,et al.  A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo‐lipiodolization , 2006, Hepatology.

[14]  B. Portmann,et al.  Reactivation of latent hepatitis B virus infection with HIV-related immunosuppression , 2006, International journal of STD & AIDS.

[15]  R. Liang,et al.  Proteomic identification of stress-response heat shock protein markers associated with tumor recurrence in patients with hepatocellular carcinoma , 2006 .

[16]  G. Cirillo,et al.  Heart transplantation in patients with chronic hepatitis B: clinical evolution, molecular analysis, and effect of treatment. , 2005, Transplantation.

[17]  N. Leung,et al.  Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy , 2005, Gut.

[18]  C. Chu,et al.  Genotype C hepatitis B virus infection is associated with a higher risk of reactivation of hepatitis B and progression to cirrhosis than genotype B: a longitudinal study of hepatitis B e antigen-positive patients with normal aminotransferase levels at baseline. , 2005, Journal of hepatology.

[19]  T. Mok,et al.  Prevention of Hepatitis B Virus Reactivation in Patients With Nasopharyngeal Carcinoma With Lamivudine , 2005, American journal of clinical oncology.

[20]  S. Moreno,et al.  Reactivation of hepatitis B in an HIV-infected patient with antibodies against hepatitis B core antigen as the only serological marker , 2005, European Journal of Clinical Microbiology and Infectious Diseases.

[21]  Thomas Berg,et al.  Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. , 2005, The New England journal of medicine.

[22]  Y. Liaw,et al.  Asian‐Pacific consensus statement on the management of chronic hepatitis B: a 2005 update , 2005, Liver international : official journal of the International Association for the Study of the Liver.

[23]  D. Fong,et al.  Clinical significance of intrahepatic hepatitis B virus covalently closed circular DNA in chronic hepatitis B patients who received cytotoxic chemotherapy. , 2005, Blood.

[24]  E. Iannitto,et al.  Hepatitis B virus reactivation and alemtuzumab therapy , 2005, European journal of haematology.

[25]  Chien-Jen Chen,et al.  Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. , 2005, Journal of the National Cancer Institute.

[26]  H. Doerr,et al.  HBV reactivation after kidney transplantation. , 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[27]  H. Okamoto,et al.  Reactivation of precore mutant hepatitis B virus leading to fulminant hepatic failure following cytotoxic treatment , 1992, Digestive Diseases and Sciences.

[28]  C. Degott,et al.  Fulminant hepatitis due to reactivation of chronic hepatitis B virus infection after allogeneic bone marrow transplantation , 1988, Digestive Diseases and Sciences.

[29]  H. Koga,et al.  Prophylactic Lamivudine Administration Prevents Exacerbation of Liver Damage in HBe Antigen Positive Patients with Hepatocellular Carcinoma Undergoing Transhepatic Arterial Infusion Chemotherapy , 2004, The American Journal of Gastroenterology.

[30]  W. Yeo,et al.  Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients , 2004, Breast Cancer Research and Treatment.

[31]  T. Mok,et al.  Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  Chih-Hung Hsu,et al.  Doxorubicin activates hepatitis B virus (HBV) replication in HBV-harboring hepatoblastoma cells. A possible novel mechanism of HBV reactivation in HBV carriers receiving systemic chemotherapy. , 2004, Anticancer research.

[33]  J. Jang,et al.  Transarterial chemo-lipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinoma. , 2004, Journal of hepatology.

[34]  F. González‐Huix,et al.  Chronic hepatitis B reactivation following infliximab therapy in Crohn’s disease patients: need for primary prophylaxis , 2004, Gut.

[35]  W. Lau,et al.  Outcome of lamivudine resistant hepatitis B virus mutant post‐liver transplantation on lamivudine monoprophylaxis , 2004, Clinical transplantation.

[36]  C. Gibbs,et al.  Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. , 2004, Gastroenterology.

[37]  W. Yeo,et al.  Lamivudine for the prevention of hepatitis B virus reactivation in hbsag seropositive cancer patients undergoing cytotoxic chemotherapy , 2004 .

[38]  M. Beksac,et al.  Lamivudine prophylaxis for prevention of chemotherapy‐induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies , 2004, Journal of viral hepatitis.

[39]  W. Yeo,et al.  High hepatitis B virus (HBV) DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing cytotoxic chemotherapy , 2004, Journal of viral hepatitis.

[40]  A. Bilici,et al.  Reactivation of hepatitis B virus infection with cytotoxic therapy in non-Hodgkin’s lymphoma , 2004, Medical oncology.

[41]  T. Chao,et al.  Preemptive use of lamivudine in breast cancer patients carrying hepatitis B virus undergoing cytotoxic chemotherapy: a longitudinal study. , 2004, Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer.

[42]  W. Su,et al.  Emergence of YMDD mutant hepatitis B virus after allogeneic stem cell transplantation from a HBsAG-positive donor during lamivudine prophylaxis. , 2004, Haematologica.

[43]  W. Su,et al.  Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy , 2004, Annals of Hematology.

[44]  T. Chao,et al.  Preemptive use of lamivudine in breast cancer patients carrying hepatitis B virus undergoing cytotoxic chemotherapy: a longitudinal follow-up , 2004, Supportive Care in Cancer.

[45]  D. Fong,et al.  Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. , 2003, Gastroenterology.

[46]  Eunkyoung Kim,et al.  The prophylactic use of lamivudine can maintain dose-intensity of adriamycin in hepatitis-B surface antigen (HBs Ag)-positive patients with Non-Hodgkin's lymphoma who receive cytotoxic chemotherapy. , 2003, Journal of Korean medical science.

[47]  E. Thiel,et al.  Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. , 2003, Blood.

[48]  V. Cheng,et al.  Current issues and treatment of fulminant hepatic failure including transplantation in Hong Kong and the Far East. , 2003, Seminars in liver disease.

[49]  R. Kumashiro,et al.  Investigation of associating factors in exacerbation of liver damage after chemotherapy in patients with HBV-related HCC. , 2003, Hepatology research : the official journal of the Japan Society of Hepatology.

[50]  Haiyang Xie,et al.  The effect of mycophenolate acid on hepatitis B virus replication in vitro. , 2003, Hepatobiliary & pancreatic diseases international : HBPD INT.

[51]  W. Yeo,et al.  Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: A prospective study , 2003, Journal of medical virology.

[52]  J. Molina,et al.  Reactivation of HBV replication in HIV-HBV infected patients. , 2003, The American journal of medicine.

[53]  J. Whang‐Peng,et al.  Steroid‐free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV‐carriers with lymphoma , 2003, Hepatology.

[54]  Barbara L. Smith,et al.  Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  E. Jury.  EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). , 2003 .

[56]  A. Lok,et al.  EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). , 2003, Journal of hepatology.

[57]  F. Salvatore,et al.  Hepatitis B virus reactivation after fludarabine-based regimens for indolent non-Hodgkin's lymphomas: high prevalence of acquired viral genomic mutations. , 2003, Haematologica.

[58]  M. Asaka,et al.  Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma , 2003, Annals of Hematology.

[59]  E. Koay,et al.  Prophylactic lamivudine prevents hepatitis B reactivation in chemotherapy patients , 2002, Alimentary pharmacology & therapeutics.

[60]  D. Fong,et al.  Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation , 2002, Hepatology.

[61]  O. Shibolet,et al.  Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. , 2002, Blood.

[62]  H. Einsele,et al.  Successful antiviral treatment for fulminant reactivated hepatitis B after autologous stem cell transplantation and prophylaxis during subsequent allogeneic stem cell transplantation , 2002, Annals of Hematology.

[63]  Y. Wen,et al.  High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. , 2002, Blood.

[64]  R. Torella,et al.  Efficacy of lamivudine to prevent hepatitis reactivation in hepatitis B virus-infected patients treated for non-Hodgkin lymphoma. , 2002, Blood.

[65]  Sheng-Nan Lu,et al.  Lamivudine for the treatment of hepatitis B virus reactivation following chemotherapy for non‐Hodgkin's lymphoma , 2002, British journal of haematology.

[66]  T. Chan,et al.  Efficacy of famciclovir in the treatment of lamivudine resistance related to an atypical hepatitis B virus mutant. , 2002, Transplantation.

[67]  G. Lau,et al.  Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy — pathogenesis and management , 2001, Reviews in medical virology.

[68]  H. Kumada,et al.  [Chronic hepatitis B]. , 2001, Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology.

[69]  I. Dervite,et al.  Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. , 2001, The New England journal of medicine.

[70]  K. Takenaka,et al.  Lamivudine and Glycyrrhizin for Treatment of Chemotherapy-Induced Hepatitis B Virus (HBV) Hepatitis in a Chronic HBV Carrier with Non-Hodgkin Lymphoma , 2001, Leukemia & lymphoma.

[71]  W. Wilson,et al.  Reactivation of chronic hepatitis B infection following intensive chemotherapy and successful treatment with lamivudine: a case report and review of the literature. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[72]  C. Manegold,et al.  Reactivation of hepatitis B virus replication accompanied by acute hepatitis in patients receiving highly active antiretroviral therapy. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[73]  W. Yeo,et al.  Sequence variations of precore/core and precore promoter regions of hepatitis B virus in patients with or without viral reactivation during cytotoxic chemotherapy , 2000, Journal of viral hepatitis.

[74]  M. Yağcı,et al.  Fludarabine and risk of hepatitis B virus reactivation in chronic lymphocytic leukemia , 2000, American journal of hematology.

[75]  W. Yeo,et al.  Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours: Precore/core mutations may play an important role , 2000, Journal of medical virology.

[76]  R. Fanin,et al.  Lamivudine for the prevention of hepatitis B virus reactivation during autologous stem cell transplantation. A case report. , 2000, Haematologica.

[77]  T. Mok,et al.  Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy , 1999, Journal of medical virology.

[78]  M. Vovk,et al.  Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients. , 1999, Hepato-gastroenterology.

[79]  C. Alexopoulos,et al.  Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumours , 1999, British Journal of Cancer.

[80]  D. Crawford,et al.  C ASE R EPORT: Lamivudine therapy for submassive hepatic necrosis due to reactivation of hepatitis B following chemotherapy , 1999, Journal of gastroenterology and hepatology.

[81]  F. Zoulim,et al.  Réactivation virale B après greffe de moelle allogénique chez un malade précédemment guéri d'une hépatite virale B. , 1999 .

[82]  R. Liang,et al.  Hepatitis B virus infection and bone marrow transplantation. , 1999, Critical reviews in oncology/hematology.

[83]  E. De Clercq,et al.  Mycophenolic acid, an immunosuppressive agent, inhibits HBV replication in vitro , 1999, Journal of viral hepatitis.

[84]  F. Zoulim,et al.  [Hepatitis B virus reactivation after allogeneic bone marrow transplantation in a patient previously cured of hepatitis B]. , 1999, Gastroenterologie clinique et biologique.

[85]  G. Lau,et al.  Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[86]  E. Keeffe,et al.  Lamivudine therapy for chemotherapy-induced reactivation of hepatitis B virus infection , 1999, American Journal of Gastroenterology.

[87]  P. Vereerstraeten,et al.  Reactivation of hepatitis B after transplantation in patients with pre-existing anti-hepatitis B surface antigen antibodies: report on three cases and review of the literature. , 1998, Transplantation.

[88]  C. Rieux,et al.  Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation: a retrospective study of 37 patients with pretransplant anti-HBs and anti-HBc. , 1998, Transplantation.

[89]  T. Benzing,et al.  Occurrence and management of hepatitis B virus reactivation following kidney transplantation. , 1998, Clinical nephrology.

[90]  B. Chapman,et al.  Successful treatment with lamivudine for fulminant reactivated hepatitis B infection following intensive therapy for high-grade non-Hodgkin's lymphoma. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[91]  R. Liang,et al.  Use of famciclovir to prevent HBV reactivation in HBsAg-positive recipients after allogeneic bone marrow transplantation. , 1998, Journal of hepatology.

[92]  Y. Liaw.  Hepatitis viruses under immunosuppressive agents , 1998, Journal of gastroenterology and hepatology.

[93]  O. Ilhan,et al.  Hepatitis B virus infection in allogeneic bone marrow transplantation , 1997, Bone Marrow Transplantation.

[94]  R. Liang,et al.  Hepatic events after bone marrow transplantation in patients with hepatitis B infection: a case controlled study , 1997, Bone Marrow Transplantation.

[95]  S. Shimano,et al.  Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[96]  M. Manns,et al.  Reactivated fulminant hepatitis B virus replication after bone marrow transplantation: clinical course and possible treatment with ganciclovir. , 1996, Journal of hepatology.

[97]  A. Burroughs,et al.  Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis , 1996, The Lancet.

[98]  M. Barros,et al.  Active replication of hepatitis B virus (HBV) in HIV type 1 and in HIV type 2 infected patients. , 1996, Revista do Instituto de Medicina Tropical de Sao Paulo.

[99]  G. Boiteau,et al.  J. Virol. Methods , 1996, Journal of Virological Methods.

[100]  M. Loriot,et al.  Hepatitis B virus precore mutations and HBeAg negative reactivation of chronic hepatitis B after interferon therapy. , 2008, Liver.

[101]  L. Mimms,et al.  Fulminant reactivation of hepatitis B due to envelope protein mutant that escaped detection by monoclonal HBsAg ELISA , 1995, The Lancet.

[102]  G. Bonadonna,et al.  Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. , 1995, The New England journal of medicine.

[103]  F. Chisari,et al.  Hepatitis B virus immunopathogenesis. , 1995, Annual review of immunology.

[104]  S. Durrant,et al.  Fatal Reactivation of Precore Mutant Hepatitis B Virus Associated with Fibrosing Cholestatic Hepatitis after Bone Marrow Transplantation , 1994, Annals of Internal Medicine.

[105]  M. Brunetto,et al.  Role of IgM antibody to hepatitis B core antigen in the diagnosis of hepatitis B exacerbations. , 1993, Archives of virology. Supplementum.

[106]  I. Sng,et al.  Fulminant hepatic failure in non-Hodgkin lymphoma patients treated with chemotherapy. , 1992, European journal of cancer.

[107]  H. Thomas,et al.  Association of a precore genomic variant of hepatitis B virus with fulminant hepatitis , 1991, Hepatology.

[108]  Roger Williams,et al.  Treatment of HBV reactivation after withdrawal of immunosuppression , 1991, The Lancet.

[109]  A. Lok,et al.  Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. , 1991 .

[110]  L. Corey,et al.  Allogeneic marrow transplantation in patients positive for hepatitis B surface antigen. , 1991, Blood.

[111]  T. Chan,et al.  Hepatitis B infection in patients with lymphomas , 1990, Hematological oncology.

[112]  P. Pontisso,et al.  Hepatitis B virus (HBV) infection and liver disease after allogeneic bone marrow transplantation: a report of 30 cases. , 1990, Bone marrow transplantation.

[113]  M. Sherman,et al.  Fulminant hepatitis as a consequence of reactivation of hepatitis B virus infection after discontinuation of low-dose methotrexate therapy. , 1990, Annals of internal medicine.

[114]  M. Vidaud,et al.  Reactivation of hepatitis B virus by corticosteroids in a case of idiopathic nephrotic syndrome. , 1990, Nephron.

[115]  A. Lok,et al.  Fatal reactivation of chronic hepatitis B virus infection following withdrawal of chemotherapy in lymphoma patients. , 1989, The Quarterly journal of medicine.

[116]  R. Tedder,et al.  Hepatitis B virus reactivation or reinfection associated with HIV-1 infection. , 1988, AIDS.

[117]  F. Carnot,et al.  Hepatitis B virus and hepatitis B-related viral infection in renal transplant recipients. A prospective study of 90 patients. , 1988, Gastroenterology.

[118]  L. Grochow,et al.  VENOOCCLUSIVE DISEASE OF THE LIVER FOLLOWING BONE MARROW TRANSPLANTATION , 1987, Transplantation.

[119]  R. Burk,et al.  Hepatitis B virus DNA contains a glucocorticoid-responsive element. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[120]  P. Kryger.  Significance of anti-HBc IgM in the differential diagnosis of viral hepatitis. , 1985, Journal of virological methods.

[121]  L. Overby,et al.  Serodiagnosis of Recent Hepatitis B Infection by IgM Class Anti‐HBc , 2007, Hepatology.

[122]  J. Hoofnagle,et al.  Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. , 1982, Annals of internal medicine.

[123]  Y. Cossart,et al.  REACTIVATION OF HEPATITIS B AFTER TRANSPLANTATION OPERATIONS , 1977, The Lancet.

[124]  A. Zuckerman,et al.  FULMINANT HEPATIC FAILURE IN LEUKAEMIA AND CHORIOCARCINOMA RELATED TO WITHDRAWAL OF CYTOTOXIC DRUG THERAPY , 1975, The Lancet.

[125]  J. Wands,et al.  Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. , 1975, Gastroenterology.

[126]  P. Neiman,et al.  CLINICAL MANIFESTATIONS OF GRAFT‐VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL‐A-MATCHED SIBLING DONOR,S , 1974, Transplantation.

[127]  A. Skulberg,et al.  Letter: Occupational hazard of halothane. , 1974, Lancet.

[128]  G. Vyas,et al.  Australia Antigen (Hepatitis B Antigen): A Conformational Antigen Dependent on Disulfide Bonds , 1972, Science.